Intellia Therapeutics: Critical Safety Updates Are Imminent - Expect Volatility [Seeking Alpha]
Intellia Therapeutics, Inc. (NTLA)
Last intellia therapeutics, inc. earnings: 2/27 07:30 am
Check Earnings Report
US:NASDAQ Investor Relations:
ir.intelliatx.com/investor-overview
Company Research
Source: Seeking Alpha
NTLA's CRISPR/Cas9 gene editing offers potentially best-in-class, one-time therapies, but irreversible gene edits raise significant safety risks. The FDA's imminent response to the clinical hold may determine the future of both NTLA's ATTR and HAE programs, with high share price volatility expected. NTLA maintains a $670m cash position and two Phase 3 assets, but efficacy and safety data remain pivotal for investment decisions. tumsasedgars/iStock via Getty Images Investment Overview - Intellia's Major Share Price Gains Given Up After Patient Death In August and September this year I covered Intellia Therapeutics, Inc. NTLA ) in notes for Seeking Alpha, assigning stock a More on my IG service If you are interested in keeping up to date with stocks making moves within the biotech, pharma and healthcare industries, and understanding the key trends and catalysts driving valuations ahead of the market, why not subscribe to my weekly newsletter via my Investing Group, Hagger
Show less
Read more
Impact Snapshot
Event Time:
NTLA
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
NTLA alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
NTLA alerts
High impacting Intellia Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
NTLA
News
- Intellia Therapeutics, Inc. (NTLA): A Bear Case Theory [Yahoo! Finance]Yahoo! Finance
- Intellia Therapeutics (NASDAQ:NTLA) was downgraded by analysts at <a style="font-weight:bold" href="https://www.wallstreetzen.com/newsletters/zen-ratings?ticker=NTLA&utm_campaign=getratings&utm_medium=online&utm_source=MarketBeat">Wall SMarketBeat
- Intellia Therapeutics (NTLA): Valuation Insights After NTLA-2001 Safety Setback and Analyst Downgrade [Yahoo! Finance]Yahoo! Finance
- Intellia Therapeutics (NTLA) Downgraded After Safety Concerns and Regulatory Delays Slow Gene-Editing Progress [Yahoo! Finance]Yahoo! Finance
- KLKB1 Inhibitors Market to Reach New Heights by 2034 Owing to the Launch of Novel Therapies | DelveInsight [Yahoo! Finance]Yahoo! Finance
NTLA
Earnings
- 11/6/25 - Beat
NTLA
Sec Filings
- 11/12/25 - Form SCHEDULE
- 11/12/25 - Form SCHEDULE
- 11/10/25 - Form 8-K
- NTLA's page on the SEC website